New gene therapy combo tackles aggressive lymphoma in early trial
NCT ID NCT06743503
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study is testing a new gene therapy called UB-VV400, alone and with the drug rapamycin, in 70 adults with relapsed or refractory large B-cell lymphoma. The main goals are to find safe doses and check for side effects. Researchers will also look for signs that the treatment shrinks tumors. The trial includes people who have and have not had prior CAR T-cell therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UB-VV400 (a gene therapy) and rapamycin (an immunosuppressant drug)
What this could lead to
If it works, this could offer a new treatment option for people with aggressive B-cell lymphoma that has not responded to other therapies, including prior CAR T-cell therapy.
What could go wrong
This is a very early (Phase 1) trial with only 70 participants, so it is primarily testing safety and dosing. It may not show strong anti-cancer effects, and side effects from the gene therapy or rapamycin are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGTianjin, China
Contact
Contact
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, China
Contact